Paradigm Biopharmaceuticals Moves to Reach Patient Recruitment Milestone in Phase 3 Knee Osteoarthritis Trial

MT Newswires Live07:10

Paradigm Biopharmaceuticals (ASX:PAR) said it has the required number of participants to meet the 25% recruitment milestone for its phase 3 PARA_OA_012 clinical trial, according to a Tuesday filing with the Australian bourse.

The trial is evaluating the company's drug candidate, injectable pentosan polysulfate sodium, for the potential treatment of knee osteoarthritis, the filing said.

The company expects to start dosing a number of participants in the trial next year, and sees the 50% recruitment milestone achieved shortly after the completion of the 25% dosing milestone, the filing added.

The company said it is on track for an interim analysis of the trial in mid-2026. The primary endpoint analysis for the full patient group is expected in the fourth quarter of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593456501?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-23 07:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593456501","market":"nz","top_or_hot":-1,"title":"Paradigm Biopharmaceuticals Moves to Reach Patient Recruitment Milestone in Phase 3 Knee Osteoarthritis Trial","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PBIGF\">Paradigm Biopharmaceuticals</a> (ASX:PAR) said it has the required number of participants to meet the 25% recruitment milestone for its phase 3 PARA_OA_012 clinical trial, according to a Tuesday filing with the Australian bourse.</p><p>The trial is evaluating the company's drug candidate, injectable pentosan polysulfate sodium, for the potential treatment of knee osteoarthritis, the filing said.</p><p>The company expects to start dosing a number of participants in the trial next year, and sees the 50% recruitment milestone achieved shortly after the completion of the 25% dosing milestone, the filing added.</p><p>The company said it is on track for an interim analysis of the trial in mid-2026. The primary endpoint analysis for the full patient group is expected in the fourth quarter of 2026.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Paradigm Biopharmaceuticals Moves to Reach Patient Recruitment Milestone in Phase 3 Knee Osteoarthritis Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nParadigm Biopharmaceuticals Moves to Reach Patient Recruitment Milestone in Phase 3 Knee Osteoarthritis Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-23 07:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PBIGF\">Paradigm Biopharmaceuticals</a> (ASX:PAR) said it has the required number of participants to meet the 25% recruitment milestone for its phase 3 PARA_OA_012 clinical trial, according to a Tuesday filing with the Australian bourse.</p><p>The trial is evaluating the company's drug candidate, injectable pentosan polysulfate sodium, for the potential treatment of knee osteoarthritis, the filing said.</p><p>The company expects to start dosing a number of participants in the trial next year, and sees the 50% recruitment milestone achieved shortly after the completion of the 25% dosing milestone, the filing added.</p><p>The company said it is on track for an interim analysis of the trial in mid-2026. The primary endpoint analysis for the full patient group is expected in the fourth quarter of 2026.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2593456501","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593456501","pubTimestamp":1766445036,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Paradigm Biopharmaceuticals  said it has the required number of participants to meet the 25% recruitment milestone for its phase 3 PARA_OA_012 clinical trial, according to a Tuesday filing with the Australian bourse.The trial is evaluating the company's drug candidate, injectable pentosan polysulfate sodium, for the potential treatment of knee osteoarthritis, the filing said.The company expects to start dosing a number of participants in the trial next year, and sees the 50% recruitment milestone achieved shortly after the completion of the 25% dosing milestone, the filing added.The company said it is on track for an interim analysis of the trial in mid-2026. The primary endpoint analysis for the full patient group is expected in the fourth quarter of 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","BK7508":"医药生物股","PAR.AU":"PARADIGM BIOPHARMACEUTICALS"},"translate_title":"Paradigm Biopharmaceuticals在3期膝骨关节炎试验中达到患者招募里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PAR.AU":1},"content_text":"Paradigm Biopharmaceuticals (ASX:PAR) said it has the required number of participants to meet the 25% recruitment milestone for its phase 3 PARA_OA_012 clinical trial, according to a Tuesday filing with the Australian bourse.The trial is evaluating the company's drug candidate, injectable pentosan polysulfate sodium, for the potential treatment of knee osteoarthritis, the filing said.The company expects to start dosing a number of participants in the trial next year, and sees the 50% recruitment milestone achieved shortly after the completion of the 25% dosing milestone, the filing added.The company said it is on track for an interim analysis of the trial in mid-2026. The primary endpoint analysis for the full patient group is expected in the fourth quarter of 2026.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593456501","isCrawlerRequest":true}